Life Sciences cybersecurity, knowing your first line of defense and continuously improving it
Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…
Key industry and government regulations provide a cybersecurity foundation in advanced therapies
Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…
Cybersecurity success in advanced therapies starts by prioritizing security as a “Way of working”
Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…
Cybersecurity challenges in advanced therapies — introducing five strategies for success
Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…
Lykan Bioscience and Vineti Announce Partnership to Advance Cell-based Therapies from Clinical to Commercialization
Lykan Bioscience’s world-class manufacturing capabilities, integrated with Vineti’s leading digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacturing…
Vineti announces agreement with Imvax to utilize Vineti’s PTM Essentials™ solution
Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more patients as fast as possible
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...
A fresh start for advanced therapy clinical trials
A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...
A true platform is the engine for advanced therapies
A Vineti technology perspective from Chief Technology Officer Phil Calvin Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader...
Now is the time for proven technology that drives scale
A Vineti technology perspective from CEO and Co-founder Amy DuRoss The underlying medical science behind cell and gene therapies continues...
Q&A with Dr. Mike Pellini: the need for advanced software to scale cell and gene therapies
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former...
Design for personalized therapies: reframing “delight” as the goal
Sometimes, in the world of UX and product design, “delight” means getting out of the way. Read about general approaches...